BOSTON ( TheStreet) -- The biotech calendar for the second half of 2011 is filled with drug approval decisions and clinical trial outcomes, enough to keep biotech stocks jumping for the remainder of the year.

Biotech investors crave tradeable events, but keeping track of clinical trials and Food and Drug Administration drug approvals can be a challenge. To make the job easier, I've compiled a list of 10 biotech stock trades for the second half of 2011.

Each of these biotech stock trades is tied to a pivotal event expected to trigger in the next six months -- either a looming drug approval decision by the FDA or the release of results from an important mid- or late-stage clinical trial. These 10 biotech stock trades were selected from a larger list of 2011 biotech catalysts because they have a greater likelihood to produce significant stock price volatility or represent a watershed moment in the lifeline of the company highlighted.

Represented here are three pending FDA drug approvals, five phase III clinical trials and two phase II clinical trials -- all of which should occur in the second half of the year.

If you liked this article you might like

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

We're Swimming in a Sea of Green This A.M.

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Shark Bites: Move Along, No Volatility to See Here

Biotech Movers: Sangamo, Epizyme, Revance